TherapeuticsMD, Inc. (TXMD)
NASDAQ: TXMD · Real-Time Price · USD
1.150
+0.030 (2.68%)
Jun 18, 2025, 11:55 AM - Market open
TherapeuticsMD Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 1.84 | 1.76 | 1.3 | 69.96 | 2.57 | 64.87 | Upgrade
|
| Revenue Growth (YoY) | 53.55% | 35.25% | -98.14% | 2619.12% | -96.03% | 30.67% | Upgrade
|
| Cost of Revenue | - | - | - | 1.4 | 1.4 | 15.98 | Upgrade
|
| Gross Profit | 1.84 | 1.76 | 1.3 | 68.57 | 1.17 | 48.9 | Upgrade
|
| Selling, General & Admin | 4.5 | 4.74 | 8.9 | 56.71 | 72.75 | 192.87 | Upgrade
|
| Research & Development | - | - | - | - | - | 10.43 | Upgrade
|
| Operating Expenses | 4.97 | 5.25 | 9.83 | 57.9 | 72.75 | 203.31 | Upgrade
|
| Operating Income | -3.13 | -3.49 | -8.52 | 10.66 | -71.58 | -154.41 | Upgrade
|
| Interest Expense | -0 | - | - | - | - | -28.58 | Upgrade
|
| Other Non Operating Income (Expenses) | 1.04 | 1.17 | 0.78 | -0.12 | 0.27 | 0.6 | Upgrade
|
| EBT Excluding Unusual Items | -2.1 | -2.33 | -7.74 | 10.55 | -71.31 | -182.39 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | -9.47 | - | - | Upgrade
|
| Asset Writedown | -1.36 | -1.27 | - | - | - | -1.13 | Upgrade
|
| Other Unusual Items | 1.25 | 1.25 | - | - | -8 | - | Upgrade
|
| Pretax Income | -2.2 | -2.34 | -7.74 | 1.07 | -79.31 | -183.52 | Upgrade
|
| Income Tax Expense | -0.06 | -0.03 | -0.04 | - | - | - | Upgrade
|
| Earnings From Continuing Operations | -2.14 | -2.31 | -7.7 | 1.07 | -79.31 | -183.52 | Upgrade
|
| Earnings From Discontinued Operations | 0.04 | 0.13 | -2.58 | 110.92 | -93.11 | - | Upgrade
|
| Net Income | -2.1 | -2.18 | -10.28 | 112 | -172.42 | -183.52 | Upgrade
|
| Net Income to Common | -2.1 | -2.18 | -10.28 | 112 | -172.42 | -183.52 | Upgrade
|
| Shares Outstanding (Basic) | 12 | 12 | 10 | 9 | 8 | 6 | Upgrade
|
| Shares Outstanding (Diluted) | 12 | 12 | 10 | 9 | 8 | 6 | Upgrade
|
| Shares Change (YoY) | 5.99% | 10.45% | 11.48% | 17.66% | 44.39% | 11.89% | Upgrade
|
| EPS (Basic) | -0.18 | -0.19 | -0.98 | 12.41 | -21.66 | -33.29 | Upgrade
|
| EPS (Diluted) | -0.19 | -0.19 | -0.99 | 11.95 | -21.66 | -33.50 | Upgrade
|
| Free Cash Flow | 1.41 | 0.73 | -48.14 | -4.08 | -142.73 | -159.68 | Upgrade
|
| Free Cash Flow Per Share | 0.12 | 0.06 | -4.61 | -0.43 | -17.93 | -28.96 | Upgrade
|
| Gross Margin | 100.00% | 100.00% | 100.00% | 98.00% | 45.51% | 75.38% | Upgrade
|
| Operating Margin | -170.18% | -198.30% | -654.61% | 15.24% | -2781.85% | -238.02% | Upgrade
|
| Profit Margin | -114.07% | -123.85% | -789.40% | 160.08% | -6700.93% | -282.90% | Upgrade
|
| Free Cash Flow Margin | 76.43% | 41.57% | -3697.46% | -5.83% | -5547.10% | -246.14% | Upgrade
|
| EBITDA | -2.66 | -2.98 | -8.08 | 11.86 | -70.84 | -150.34 | Upgrade
|
| EBITDA Margin | -144.59% | -169.39% | - | 16.95% | - | -231.75% | Upgrade
|
| D&A For EBITDA | 0.47 | 0.51 | 0.44 | 1.19 | 0.74 | 4.07 | Upgrade
|
| EBIT | -3.13 | -3.49 | -8.52 | 10.66 | -71.58 | -154.41 | Upgrade
|
| EBIT Margin | -170.18% | -198.30% | - | 15.24% | - | -238.02% | Upgrade
|
| Revenue as Reported | - | - | - | 69.96 | 2.57 | 64.87 | Upgrade
|
| Advertising Expenses | - | - | - | - | - | 35.8 | Upgrade
|
Updated Nov 12, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.